Neurotech International Ltd (ASX:NTI) Share Price

Company Profile

Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUS
T: +61 394983132
https://www.neurotechinternational.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
18

Recommended

Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.

Jon Mills, CFA | 08 October 2025

Charts from the Australian Dividend Outlook show the sectors where they are abundant.

Shani Jayamanne | 08 October 2025

Investors may be too pessimistic about this industry.

Jon Mills, CFA | 07 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,276.20	20.30	-0.22%
CAC 40	8,060.13	85.28	1.07%
DAX 40	24,597.13	211.35	0.87%
Dow JONES (US)	46,601.78	1.20	-0.00%
FTSE 100	9,548.87	65.29	0.69%
HKSE	26,907.06	77.60	0.29%
NASDAQ	23,043.38	255.02	1.12%
Nikkei 225	48,435.64	700.65	1.47%
NZX 50 Index	13,570.86	2.38	0.02%
S&P 500	6,753.72	39.13	0.58%
S&P/ASX 200	8,969.40	25.60	-0.28%
SSE Composite Index	3,930.87	48.09	1.24%